Analysts are not impressed . They should be | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6580 of 6929  at  11/8/2019 1:45:37 PM  by

theriver


 In response to msg 6579 by  erniewerner
view thread

Re: Analysts are not impressed . They should be

Ernie, I would love your thoughts on why you expect a positive outcome from Andexxa phase 4 study. It will come out in 4 years (estimate study completion date is Nov. 2023)

I think a positive outcome would depend on what is used as "usual care." And if the usual care includes Kcentra, it'll depend on the concentration of FXa inhibitor in the blood at the time of treatment. Kcentra does not work unless the concentration of FXa inhibitor in the blood is low. That's why I wish the inclusion criteria would have tightened up to something like within 10 hours of taking FXa inhibitor rather than 15 hours.

Retrospective analysis of use of Kcentra shows about 69% hemostatic efficacy. I think Andexxa will clock in at 80% or better. For me, it's too close for comfort. I think the outcome will be more certain if the patient is treated closer to taking of Eliquis/Xarelto. Also, I'm not sure how many patients will get Kcentra as part of 'usual care.'

It will take 4 years for us to find out. That's a long time.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 383
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
6581 Re: Analysts are not impressed . They should be erniewerner 9 11/8/2019 4:34:03 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...